Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
Randomized trial demonstrated improved event free survival in adults with acute myeloid leukemia, indicating azacitidine and venetoclax may be preferred.
Key Points
Aza-ven significantly improved event free survival and overall response compared to induction chemotherapy in fit AML patients.
The trial revealed a composite remission rate of 81% for aza-ven versus 55% for induction chemotherapy (P<0.001).
Analysis employed a randomized clinical trial design assessing quality of life and hospitalization metrics across both treatment arms.
Advocates for azacitidine and venetoclax as superior options, suggesting re-evaluation of standard induction protocols.